Cargando…

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route

Buprenorphine extended‐release (BUP‐XR) formulation is a once‐monthly subcutaneous injection for the treatment of opioid use disorder (OUD). Buprenorphine undergoes extensive cytochrome P450 (CYP) 3A4 metabolism, leading to potential drug‐drug interactions (DDIs) as reported for sublingual buprenorp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kharidia, Jahnavi, Howgate, Eleanor M., Laffont, Celine M., Liu, Yongzhen, Young, Malcolm A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451859/ https://www.ncbi.nlm.nih.gov/pubmed/33750027 http://dx.doi.org/10.1002/cpdd.934

Ejemplares similares

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
por: Schmith, Virginia D., et al.
Publicado: (2019)

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy
por: Towers, Craig V., et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes
por: Chang, Hsuan-Ping, et al.
Publicado: (2023)

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials
por: Jones, Aksana K., et al.
Publicado: (2020)

Bioavailability of IgG Administered by the Subcutaneous Route
por: Berger, Melvin, et al.
Publicado: (2013)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Unusual Route of Buprenorphine Administration: An Alternative Approach for Bypassing Adverse Drug Reactions
por: Nazari, Azadeh, et al.
Publicado: (2019)

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder
por: Dong, Ruihua, et al.
Publicado: (2019)

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder
por: Laffont, Celine M., et al.
Publicado: (2022)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
por: Andorn, Anne C., et al.
Publicado: (2020)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations
por: Tchobaniouk, Lesia V, et al.
Publicado: (2019)

Compatibility of PiC Insupen Needles with a Broad Range of Pens for the Injection of Subcutaneously Administered Drugs for Diabetes
por: Nicolucci, Antonio, et al.
Publicado: (2022)

Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice
por: DeTolla, L., et al.
Publicado: (2014)

Modeling buprenorphine reduction of fentanyl-induced respiratory depression
por: Olofsen, Erik, et al.
Publicado: (2022)

Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability
por: Dickman, Andrew, et al.
Publicado: (2017)

Routes of non-traditional entry into buprenorphine treatment programs
por: Champagne-Langabeer, Tiffany, et al.
Publicado: (2020)

Raster plots machine learning to predict the seizure liability of drugs and to identify drugs
por: Matsuda, N., et al.
Publicado: (2022)

Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone
por: Garimella, Tushar, et al.
Publicado: (2014)

Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats
por: Guarnieri, M., et al.
Publicado: (2017)

In vitro safety “clinical trial” of the cardiac liability of drug polytherapy
por: Charrez, Bérénice, et al.
Publicado: (2021)

Methadone, Buprenorphine, and Street Drug Interactions with Antiretroviral Medications
por: Gruber, Valerie A., et al.
Publicado: (2010)

823 Evaluation of Drug-Drug Interaction between Asunaprevir and Methadone or Buprenorphine/Naloxone
por: Garimella, Tushar, et al.
Publicado: (2014)

Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits
por: Askar, Raad, et al.
Publicado: (2020)

Effective method for drug injection into subcutaneous tissue
por: Kim, Hyejeong, et al.
Publicado: (2017)

Service evaluation of long acting buprenorphine subcutaneous injection (BUVIDAL) in the west Lothian community addictions service
por: Martin, Amy
Publicado: (2021)

Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs
por: Lofts, Andrew, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection
por: Goutelle, Sylvain, et al.
Publicado: (2021)

Correction to: Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits
por: Askar, Raad, et al.
Publicado: (2021)

The Effects of Maternally Administered Methadone, Buprenorphine and Naltrexone on Offspring: Review of Human and Animal Data
por: Farid, W.O, et al.
Publicado: (2008)

Monthly Patient Volumes of Buprenorphine-Waivered Clinicians in the US
por: Duncan, Alexandra, et al.
Publicado: (2020)

Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine
por: Parsons, Graham, et al.
Publicado: (2020)

Manslaughter by Administering Noxious Drugs
Publicado: (1908)

Administering Drugs to Rodents by Mouth
por: Paul, B. M.
Publicado: (1943)

Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates
por: Jain, Meena, et al.
Publicado: (2017)

Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder
por: Frost, Michael, et al.
Publicado: (2019)

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial
por: Lintzeris, Nicholas, et al.
Publicado: (2021)

Drug Trafficking Routes and Hepatitis B in Injection Drug Users, Manipur, India
por: Datta, Sibnarayan, et al.
Publicado: (2006)

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities
por: Li, Yang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fi5spq3o8p8eh7gum4ccnnsc2d